Kane Biotech appoints Mark Nawacki as Chairman of its Board of Directors alongside Philip Renaud stepping to the role of Vice-Chair

– CANADA, Winnipeg –  Kane Biotech Inc. (TSX: KNE | OTC: KNBIF) today announced that current Board member Mark Nawacki will take over as Chairman of the Board alongside Philip Renaud stepping to the role of Vice-Chair.

“Over the past two years we have made significant progress developing and commercializing our technologies in both animal health and skin care where we’ve built two very promising businesses. As outgoing Chairman and largest shareholder, it is my belief that as the Company approaches a number of anticipated inflection points in Wound Care, it would be best served by having an experienced executive with a deep understanding of the biotechnology sector in Canada and around the world. I will remain a board member and will look to grow my position in Kane Biotech as Marc Edwards, CEO, and his team continue to achieve their ambitious goals,” said Philip Renaud, Vice-Chair and outgoing Chairman.

About Mark Nawacki

Mark Nawacki is currently the President & CEO of Searchlight Pharma Inc., a Canadian-based specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products. Before this, Mr. Nawacki served as EVP, Business and Corporate Development of Paladin Labs, a leading Canadian specialty pharmaceutical company, from 2003 to 2014.

He also currently sits on the Board of Intelgenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT).

Mark Nawacki said, “Firstly I would like to thank Philip for all his hard work and stewardship of Kane Biotech. I am honored to take the role of Chairman to guide the Company to the next level and draw from my experience of successfully commercializing technologies”.

Mr. Nawacki holds a BA in International Relations and Russian and East European Studies from the University of Toronto, an MBA also from the University of Toronto, and is a Canadian-designated CPA.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks), and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, bluestem, silk stem, gold stem, coactive+, DermaKB, and DermaKB Biofilm are trademarks of Kane Biotech Inc.

For more information: http://www.kanebiotech.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team